Read the latest WaveData articles, or search through our archive.
Follow us on LinkedIn to keep up to date with WaveData news, articles, insights and analysis
Please use complete words when searching…
UK Price Watch – Generics Bulletin
Check out the latest UK Price Watch article in the Generics Bulletin for analysis and insight on June 2026 product launches, the biggest risers, the biggest fallers and the fastest movers…. with market data provided by WaveData.
What will my brand be worth after LOE?
If your brand is approaching its loss of exclusivity you maybe starting to think about the launch of generics. You’ll be concerned with how long you can maintain margin and retain he brand. Is it worth brand equalising, and if so for how long? In these situations, it’s very useful to have price analogues to help you forecast, or at least make some intelligent guesses about what market prices will be like in the months and years after loss of exclusivity.
How will generics compete with my brand after loss of exclusivity?
We often get asked to provide historical market prices so that manufacturers can gain an understanding of the competition their brand is likely to face after loss of exclusivity.
Charles Joynson, WaveData MD, conducts a deep dive on Respiratory Brands and Parallel Imports.
The graph shows the average PI price for a group of respiratory products. Each of the branded products shown in the chart is heavily effected by parallel imports as they were the most commonly traded PI respiratory products in May 2026, and in the top 12 of all PI’d products in that month.
Generics Bulletin – UK Price Watch
Check out the latest UK Price Watch article in the Generics Bulletin for analysis and insight on May 2026 product launches, the biggest risers, the biggest fallers and the fastest movers…. with market data provided by WaveData. Dave Wallace, editor at Generics...
Charles Joynson, WaveData MD, takes a look at Aspirin E/C Tabs 75mg 28 long term price trends.
Looking at the long-term graph comparing the English Drug Tariff with the average UK market price it does look as if there has been a profit squeeze on this product, primarily affecting Pharmacies, but this has resulted in a series of price bounces and shortages.
UK Price Watch
Check out the latest UK Price Watch article in the Generics Bulletin for analysis and insight on April 2026 product launches, the biggest risers, the biggest fallers and the fastest movers…. with market data provided by WaveData.
Generics Bulletin UK Price Watch March 2026
Check out the latest UK Price Watch article in the Generics Bulletin for analysis and insight on March 2026 product launches, the biggest risers, the biggest fallers and the fastest movers…. with market data provided by WaveData.
Stop the Bounce……
Charles Joynson takes a look at the long term changes to the commercial behaviour of Gabapentin Caps 300mg 100
When Gabapentin Caps 300mg 100 were launched way back in December 2003 prices came down from over £40 to less than £10 in just three years. It could have been this shock to the product price that resulted in a series of four price bounces and shortages or it could’ve been the disruption to reimbursement with the English Drug Tariff going up and down like a yo-yo in the early years. Whether it was both of these causes or just one, the erratic behaviour of the English Drug Tariff would not have helped.
Do Concessions Come in Cycles?
When we look at the graph showing the number of concessions granted each month it does appear to have a series of concession cycles, with the first one starting in 2017, the second in 2022 and the third starting at the end of 2025.
Therefore, we thought we’d compare the three and try to get to grips with why they might be happening.
Charles Joynson, WaveData MD, takes a closer look at the unpredictable pricing and profitability for Trihexyphenidyl Tabs 2mg 84.
Here is a product that the market seems to have abandoned. In February the average market price for this product was £134.69 per pack, the Drug Tariff was £86.80, and it had a concession of £123.63.
Charles Joynson, WaveData MD undertakes some analysis on short dated products.
When a product is in seriously short supply, Pharmacies will get their hands on any stock they can to satisfy their customers. This sometimes means that they have to get short dated stock. If they have no long dated alternative, short dated will have to do. The presence of short dated stock in the market gives us a clue about the availability or shortage of that particular product.
Concessions granted by year and by category
Here at WaveData we keep a close eye on the number of concessions granted to individual products each month and have been doing so since they were launched in November 2010. We have always assumed the Category M is the primary source of concessions and of the linked shortages, but this month Charles Joynson, WaveData MD, has taken a closer look to see if this is correct.
Category H Profitability Analysis
There has been a lot of discussion about Category H at recent events, online and on socials.
Charles Joynson, WaveData MD, poses the question; ‘Will it cut another group of generics to the bone and seriously damaged pharmacy and supplier profitability? Or will it increase profitability for the supply chain?’
Are Parallel Imports Profitable for Pharmacies?
We know that pharmacies buying generics are making a loss when they dispense. Previous analysis, available on the Wavedata.co.uk articles page, shows that over 1200 generic products each month are unprofitable.
However, what about parallel imports, are they profitable products for pharmacies to dispense or are pharmacies losing money with these as well?
Medicine Matters Podcast Episode 6
Charles Joynson, WaveData MD, was delighted to join Jeremy Durrant, Director of Communications and External Engagement at Medicines UK, in the latest episode of their podcast Medicine Matters.
House of Lords Public Services Committee on Shortages
The House of Lords Public Services Committee has published its report concluding its medicines security inquiry. They argued that it is vital that the UK has strong, resilient medicine supply chains and emphasised the need for clear, proactive leadership. The report...
Charles Joynson comments on Aspirin supply disruption
Aspirin has been added to the government’s ‘No Export’ list and to the list of concessions meant to help pharmacies break even when they dispense this hard to get product. Prices are rising in the UK market, so we thought we’d have a look at the longer term, specifically drilling into the wholesale activity and the number of times they list Aspirin packs to their price lists.
Generic Market Prices versus the Drug Tariff
To start the year off with a bang, we thought we’d compare the generic product prices we get from our Pharmacy and Dispensing Doctor data suppliers with the Drug Tariff for each product.
Charles Joynson shares some good news for diabetic patients and pharmacies.
Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus.
The average market price for this medicine normally hovers around the £5 mark but in late 2019 the drug tariff started to come down from over £10.42 toward £5.47 by February 2021.
Follow us: